EP2922826A4 - Methods of treating a disease or disorder associated with bruton's tyrosine kinase - Google Patents
Methods of treating a disease or disorder associated with bruton's tyrosine kinaseInfo
- Publication number
- EP2922826A4 EP2922826A4 EP13856920.7A EP13856920A EP2922826A4 EP 2922826 A4 EP2922826 A4 EP 2922826A4 EP 13856920 A EP13856920 A EP 13856920A EP 2922826 A4 EP2922826 A4 EP 2922826A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- bruton
- disease
- treating
- methods
- tyrosine kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261728701P | 2012-11-20 | 2012-11-20 | |
US201261728703P | 2012-11-20 | 2012-11-20 | |
US201361799761P | 2013-03-15 | 2013-03-15 | |
US201361870718P | 2013-08-27 | 2013-08-27 | |
US201361870720P | 2013-08-27 | 2013-08-27 | |
PCT/US2013/070766 WO2014081709A2 (en) | 2012-11-20 | 2013-11-19 | Methods of treating a disease or disorder associated with bruton's tyrosine kinase |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2922826A2 EP2922826A2 (en) | 2015-09-30 |
EP2922826A4 true EP2922826A4 (en) | 2016-08-03 |
Family
ID=50776661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13856920.7A Withdrawn EP2922826A4 (en) | 2012-11-20 | 2013-11-19 | Methods of treating a disease or disorder associated with bruton's tyrosine kinase |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2922826A4 (en) |
TW (1) | TW201427666A (en) |
WO (1) | WO2014081709A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2922546A4 (en) * | 2012-11-20 | 2016-06-08 | Celgene Avilomics Res Inc | Methods of treating a disease or disorder associated with bruton's tyrosine kinase |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
WO2016025561A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Forms and compositions of an erk inhibitor |
CN111057021B (en) * | 2019-12-11 | 2023-05-23 | 中国药科大学 | S-triazine compound, preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011153514A2 (en) * | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1949912A3 (en) * | 1998-11-09 | 2008-08-13 | Biogen Idec, Inc. | Treatment of chronic lymphcytic leukemia (CLL) using chimeric anti-CD20 antibody |
US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
BR112013003388A2 (en) * | 2010-08-10 | 2016-07-12 | Celgene Avilomics Res Inc | besylate salt of a btk inhibitor |
US20140031325A1 (en) * | 2010-12-06 | 2014-01-30 | Celgene Corporation | Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
CN102093421B (en) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | Phosphorus substituent group-containing quinoline compound and preparation method of quinoline compound as well as pharmaceutical composition containing quinoline compound and application of pharmaceutical composition |
EP2694486B1 (en) * | 2011-04-01 | 2018-01-10 | University of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
-
2013
- 2013-11-19 WO PCT/US2013/070766 patent/WO2014081709A2/en active Application Filing
- 2013-11-19 EP EP13856920.7A patent/EP2922826A4/en not_active Withdrawn
- 2013-11-19 TW TW102142188A patent/TW201427666A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011153514A2 (en) * | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
Also Published As
Publication number | Publication date |
---|---|
TW201427666A (en) | 2014-07-16 |
WO2014081709A2 (en) | 2014-05-30 |
EP2922826A2 (en) | 2015-09-30 |
WO2014081709A3 (en) | 2015-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2770830A4 (en) | Methods of treating a bruton's tyrosine kinase disease or disorder | |
IL238571A0 (en) | Bruton's tyrosine kinase inhibitors | |
IL269511A (en) | New therapeutic approaches for treating parkinson's disease | |
IL266648B (en) | Method for treatment of parkinson's disease | |
EP2922827A4 (en) | Methods of treating a disease or disorder associated with bruton's tyrosine kinase | |
EP2925740A4 (en) | Inhibitors of bruton's tyrosine kinase | |
IL245042A0 (en) | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy | |
EP2809673A4 (en) | Cyclic molecules as bruton's tyrosine kinase inhibitors | |
SG11201602421VA (en) | Inhibitors of bruton's tyrosine kinase | |
EP2922546A4 (en) | Methods of treating a disease or disorder associated with bruton's tyrosine kinase | |
ZA201400012B (en) | Inhibitors of bruton's tyrosine kinase | |
EP2858500A4 (en) | Inhibitors of bruton's tyrosine kinase | |
ZA201308397B (en) | Inhibitors of bruton's tyrosine kinase | |
EP2844256A4 (en) | Treating neural disease with tyrosine kinase inhibitors | |
ZA201400739B (en) | Inhibitors of bruton's tyrosine kinase | |
EP2833886A4 (en) | Substituted quinolines as bruton's tyrosine kinases inhibitors | |
HK1215173A1 (en) | Methods of treating s. aureus-associated diseases | |
EP2680842A4 (en) | Methods of treating a disease or condition of the central nervous system | |
PL2959903T3 (en) | Medicine for treating eye disease | |
EP2922826A4 (en) | Methods of treating a disease or disorder associated with bruton's tyrosine kinase | |
ES2627541T8 (en) | Methods to treat Parkinson's disease | |
EP2814474A4 (en) | Methods of treating and preventing diseases and disorders of the central nervous system | |
IL242355B (en) | Cannabidiol for the prevention and treatment of graft-versus-host disease | |
EP2906225A4 (en) | Methods of treating kennedy's disease | |
EP2892538A4 (en) | Methods of treating a bruton's tyrosine kinase disease or disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150615 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20160630 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20160624BHEP Ipc: A61K 31/675 20060101AFI20160624BHEP |
|
17Q | First examination report despatched |
Effective date: 20170921 |
|
17Q | First examination report despatched |
Effective date: 20170927 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20180208 |